Controlled Hypothermic Storage for Lung Preservation: Leaving the Ice Age Behind

Abstract

Controlled hypothermic storage (CHS) is a recent advance in lung transplantation (LTx) allowing preservation at temperatures higher than those achieved with traditional ice storage. The mechanisms explaining the benefits of CHS compared to conventional static ice storage (SIS) remain unclear and clinical data on safety and feasibility of lung CHS are limited. Therefore, we aimed to provide a focus review on animal experiments, molecular mechanisms, CHS devices, current clinical experience, and potential future benefits of CHS. Rabbit, canine and porcine experiments showed superior lung physiology after prolonged storage at 10°C vs. ≤4°C. In recent molecular analyses of lung CHS, better protection of mitochondrial health and higher levels of antioxidative metabolites were observed. The acquired insights into the underlying mechanisms and development of CHS devices allowed clinical application and research using CHS for lung preservation. The initial findings are promising; however, further data collection and analysis are required to draw more robust conclusions. Extended lung preservation with CHS may provide benefits to both recipients and healthcare personnel. Reduced time pressure between procurement and transplantation introduces flexibility allowing better decision-making and overnight bridging by delaying transplantation to daytime without compromising outcome.

Introduction

Preservation of organs remains a key area for research in transplantation medicine. Several strategies to reduce organ injury during preservation have been explored. Over the past decades, organ-specific preservation solutions and ex-vivo perfusion platforms have been developed [1–4]. Currently, the standard of care for preservation remains static ice storage (SIS). Traditionally, temperature in this setting has been estimated to be around 4°C [1, 5]. However, actual temperature with SIS might be lower and result in freezing injury due to the organ contact with ice [6]. On a cellular level, the low temperatures reached with SIS decrease metabolic demand, but has also been associated with progressive mitochondrial dysfunction [7]. Interestingly, lungs are privileged because the oxygen repleted air in the expanded alveoli continues to support aerobic metabolism during preservation [8]. Recently, it has been shown that controlled hypothermic storage (CHS) of lungs at 10°C better maintains mitochondrial health during preservation [9, 10]. Therefore, the optimal temperature for hypothermic lung preservation might be found by balancing aerobic metabolism and oxygen consumption while preventing cellular exhaustion [7, 11, 12]. With SIS, cold ischemia time (CIT) for lungs is advised to be kept as short as possible to minimize cellular injury [1, 13]. The limited preservation time forces teams to perform transplant procedures at night, and restraints long-distance procurement. Overnight transplantation is associated with worse post-transplant outcomes, possibly due to limited resources and expertise, and sleep-deprived personnel [14, 15]. Lung preservation with CHS at a higher temperature has the potential to safely extend preservation time and thereby overcome logistical challenges [9, 16]. In this article we aim to provide a focus review of preclinical research, the cellular mechanisms, and the clinical experience explaining the benefits of CHS in the setting of lung transplantation (LTx).

Preclinical Data on Controlled Hypothermic Lung Storage

Over the past decades, concerns regarding optimal temperature for lung preservation have been raised due to cold-induced lung injury provoked by SIS. In 1989, Wang and colleagues (Toronto, Canada) developed an ex-vivo rabbit lung preservation model with the aim to accurately assess post-ischemic lung function [17]. For lungs with different CIT and preservation temperatures (4°C, 10°C, 15°C, 23°C, 34°C, 38°C), they assessed post-ischemic functional variables like partial pressure of arterial oxygen (PaO₂), pulmonary artery pressure (PAP) and oxygen uptake (Figure 1). Of note, the 4°C group was performed in a temperature-controlled room, and not by immediate ice contact. They hypothesized that lower temperature would improve post-ischemic lung function. However, after 12 h CIT followed by 10 min reperfusion, lungs preserved at 10°C were functionally superior to those preserved at 4°C. The 10°C group tolerated CIT periods of 18–24 h with PaO₂ and PAP similar to 30 min preservation at 4°C. The extension of CIT to 30 h deteriorated gas exchange (Figure 1). These observations raised questions regarding optimal lung preservation temperature and led to a revision of the dogma advocating cold storage of lungs at 4°C.

FIGURE 1

In 1992, Date et al. (St. Louis, Missouri) set up a canine model of orthotopic left-LTx to compare pulmonary function in lungs filled with room air after 18 h of preservation at 10°C vs. 4°C [18]. Furthermore, they conducted a pulmonary metabolic study evaluating adenosine triphosphate (ATP) levels. Functionally, gas exchange and perfusion were superior in the 10°C group with higher PaO₂ and lower pulmonary vascular resistance (PVR) immediately post-LTx. No important difference in PaO₂ or PVR was observed on day 3 (Figure 2). In addition, ATP levels remained stable during the 18 h preservation at 10°C and 4°C. Impaired lung physiology at 4°C preservation could hence not be explained by cellular ATP depletion. Therefore, it was suggested that sodium/potassium (Na+/K+) ATPase might be impaired at 4°C, leading to intracellular Na + accumulation and cellular swelling. The St. Louis researchers (1992) concluded that optimal lung preservation temperature is near 10°C [18].

FIGURE 2

Also in 1992, Nakamoto et al. (Kagawa, Japan) preserved rabbit lungs for 18 h at predetermined temperatures ranging from 4°C to 15°C [19]. Physiology was assessed with PAP, PaO₂ and wet-to-dry (W/D) ratio as a measure for edema. Pulmonary vasculature was assessed with perfusion of blood containing indocyanine green (ICG) and histopathological evaluation was performed using colloidal carbon black perfusion.

Based on mathematical regressions of W/D and PaO₂ (Figure 3), optimal temperature for lung preservation was found between 8°C and 9°C. At 8°C, superior physiology was observed, and microvasculature was intact in contrast to other groups. Each fitted sigmoid curve for W/D and PaO₂ showed an inflection point at 6°C–7°C, which seems to be a critical temperature for vascular obstruction. After 4°C preservation, carbon colloid particles were absent in capillaries and massive alveolar hemorrhage with arteriolar obstruction was seen, suggesting impaired physiology was related to vascular obstruction. However, at 15°C, carbon colloid particles were present, and centrilobular alveolar hemorrhage was observed, suggesting deterioration at 15°C was due to increased injury to the alveolocapillary membrane rather than vascular obstruction [19].

FIGURE 3

Other extended preservation experiments were performed in canine left LTx models by Keshavjee et al. (Toronto, 1989), Mayer et al. (Toronto, 1991) and a porcine left LTx model by Steen et al. (Lund, 1993) [20–23]. However, further translation of CHS to clinical practice was considered a major challenge due to lack of insights into the underlying mechanisms and logistical demands.

Three decades later, in 2021, the concept of 10°C preservation with the intention of better preserving lung physiology and metabolism re-emerged in Toronto where Ali, Cypel and colleagues developed a porcine model of lung preservation followed by ex-vivo lung perfusion (EVLP) (Figure 4A). Pig lungs were randomized to storage at 4°C (walk-in cooler) or 10°C (thermoelectric cooler) for 36 h followed by 12 h normothermic EVLP [9].

FIGURE 4

CHS at 10°C resulted in higher compliance, better oxygenation, and less edema. Furthermore, CHS was associated with upregulated expression of cytoprotective anti-oxidative metabolites (itaconate, glutamine, N-acetyl glutamine) as well as decreased perfusate protein levels of pro-inflammatory cytokines and cell-free mitochondrial DNA (mtDNA) (Figure 5) [9].

FIGURE 5

In a porcine model of orthotopic left LTx, Abdelnour-Berchtold et al. (Toronto, 2022) studied potential benefits of 10°C storage in marginal lungs injured by 5 mL gastric juice (Figure 4B) [10]. Three hours after instillation, lungs were procured and randomized to 10°C or ice for 12 h followed by LTx. As control group, five injured lungs were placed on ice for 1 h followed by LTx.

Four hours post-Tx, 10°C preservation resulted in superior selective left-lung PaO₂, compliance, and histopathological evidence of reduced acute lung injury. Based on metabolomic analysis, they found no metabolic activity for SIS. However, 10°C preservation showed active metabolism and higher levels of anti-oxidative metabolites (glutathione, ascorbate). Tissue levels of interleukin-1β were significantly lower for 10°C preservation. Compared to controls, free mtDNA was expressed less at 10°C.

These findings suggest that intentional delay of LTx by using CHS might trigger cell protective mechanisms and result in better post-LTx outcome.

Ice Is Not 4°C

The International Society for Heart and Lung Transplantation (ISHLT) consensus statement on organ preservation advises to avoid contact of organs with ice to limit cold-induced cellular injury ([6]). In transplantation, a misconception exists regarding temperatures reached by SIS, wherein it is commonly assumed that organs are maintained at 4°C. However, no temperature measurements of donor lungs during SIS were available. This misconception of 4°C might refer to the temperature at which water reaches its maximum density in a soluble state. The actual freezing temperature of water at atmospheric pressure (1013 hPa) is 0°C, at which water is present in the form of solid ice (Figure 6). Interesting to note is that slushed ice used in organ preservation is derived from 0,9%NaCl physiologic saline with a freezing point below 0°C, approximating −0,59°C. Furthermore, a saline cooling model by Robicsek et al. noted temperature drops in clinical setting to −7,1°C and osmolality differences between the center and periphery of the solid ice [25].

FIGURE 6

In the earlier described canine LTx model, temperature dropped below 1°C after 2 h of SIS [18]. In a recent preliminary study of porcine lung preservation thermodynamics, Patel et al. showed that preservation and tissue temperature reached around 0°C after 3 h of SIS (Figure 7) [26].

FIGURE 7

In a clinical study at our center (Leuven, Belgium) donor lung temperatures were measured after preservation with SIS on ice [27]. Median parenchymal surface temperature measured with a thermal camera (Figure 8) and core temperature measured with a probe (3 mm) wedged in a lower lobe bronchus was close to 0°C with SIS.

FIGURE 8

Cold-Induced Cellular Injury and the Mechanisms by Which Controlled Hypothermic Storage Protects Cellular Viability

Static Ice Storage Causes Cold-Induced Cellular Freezing Injury

Cellular structure and metabolic function are altered at low temperatures (Figure 9). Cold-induced protein denaturation is caused by changes in hydrophobic amino-acid interactions at near-freezing temperatures and are responsible for loss of stability and misfolding of globular structural proteins [28]. In tissues exposed to temperatures around 0°C, formation of ice crystals causes electrolyte and osmotic imbalances leading to mitochondrial swelling and dysfunction [29].

FIGURE 9

Cellular survival depends on ATP metabolism and the main source for ATP is aerobic metabolism in the mitochondria. Furthermore, mitochondrial injury and subsequent cell death results in the release of mtDNA which triggers inflammatory pathways [9, 30]. Mitochondrial dysfunction is also associated with increased levels of reactive oxygen species (ROS) which further propagate mitochondrial disintegration and oxidative stress [31]. Taken together, safeguarding mitochondrial function is essential to maintain organ quality during preservation.

The Role of the Na+/K + ATPase During Static Ice Storage and Controlled Hypothermic Storage

The Na+/K + ATPase maintains cell membrane potential. Dysfunction of Na+/K + ATPases results in extramitochondrial accumulation of Na+ and Ca+2 followed by impairment of the mitochondrial Na+/Ca+2 pump (NCX). ATP depletion and impaired Na+/K + ATPase function therefore cause accumulation of intramitochondrial Ca+2 resulting in mitochondrial swelling and dysfunction [32]. The intracellular accumulation of Ca+2 activates proteases which leads to an irreversibly conversion of xanthine dehydrogenase to xanthine oxidase. Xanthine oxidase and increased hypoxanthine is responsible for ROS formation during anoxic ischemia reperfusion injury (IRI) [33]. Alveolar fluid clearance (AFC) via type I and II pneumocytes depends on an osmotic gradient towards the interstitium created by Na + transport across the apical membrane through epithelial sodium channelss and basolateral Na+/K + ATPase (Figure 10).

FIGURE 10

In rabbit and canine models of lung preservation, it was shown that aerobic mitochondrial metabolism is sustained during preservation. In contrast to other solid organs, the lung is indeed privileged by its supply of oxygen in the air-filled alveoli. Interestingly, the analyses showed that ATP levels were equal during 1°C/4°C and 10°C preservation [8, 18]. Therefore, improved organ preservation with CHS cannot be explained by improved Na+/K + ATPase function. In the porcine model of lung preservation, comparative analysis of Na+/K + ATPase activity during preservation showed no significant difference between 4°C and 10°C [9]. However, Na+/K + ATPase is essential to maintain organ quality. During an experiment where Na+/K + ATPase was inhibited by ouabain during 10°C preservation and subsequent EVLP, lung physiology was significantly impaired [9].

Controlled Hypothermic Storage Favors Aerobic Mitochondrial Metabolism

It must be recognized that the mechanisms of ROS formation are different in lung tissue in comparison to other solid organs due to the presence of oxygen during ischemia. In other solid organs like the liver or heart, ischemia during preservation is coupled to anoxia, a process called anoxic ischemia. Depletion of oxygen in the alveoli impairs aerobic cellular respiration in the mitochondria. ATP synthesis is consequently shifted towards anaerobic glycolysis and phosphocreatine [8].

In a rabbit model of 24 h lung preservation, metabolic characteristics were compared at 1°C, 10°C and 22°C (Figure 11) [8]. Oxygen consumption and metabolic need increased with higher temperatures. Energy stores were depleted fastest at 22°C. 1°C preservation resulted in minimal ATP consumption with preserved glucose and glucose-6-phosphate levels over time. However, 1°C preservation beyond 4 h led to increased lactate levels in the 1°C group suggesting cell death. Conversely, lactate levels decreased over time during 10°C preservation [8, 34]. Furthermore, ATP and phosphocreatine levels were highest after 24 h of 10°C preservation.

FIGURE 11

Controlled Hypothermic Storage Favors Anti-oxidative Metabolism

In the porcine model of lung preservation after gastric juice instillation, a shift towards anti-oxidative metabolism was found for 10°C preservation [10]. Higher lung tissue levels of glutathione and ascorbate were detected after 10°C compared SIS, suggesting that CHS favors anti-oxidative metabolism. Glutathione and ascorbate are scavenger molecules that neutralize oxygen radicals and are consumed at ischemia-reperfusion injury (IRI) [35]. Higher levels of anti-oxidative metabolites reduce cellular oxidative stress and in turn better preserve mitochondrial health [9, 10, 36].

Metabolic profiling after 36 h preservation of porcine lungs showed increased tissue levels of glutamine, n-acetyl glutamine and itaconate at 10°C vs. 4°C [9]. Accumulation of succinate during ischemia acts as a potential electron store which in turn drives superoxide formation with the introduction of oxygen during reperfusion (Figure 12) [37–39]. Itaconate inhibits succinate dehydrogenase (Complex II) and decreases succinate-derived formation of ROS at reperfusion and can therefore explain the association between higher itaconate levels in lung tissue after 10°C CHS with reduced lung injury during EVLP after 36 h preservation [9, 38].

FIGURE 12

Taken together, CHS of oxygen repleted lungs appears to achieve the right balance of preventing freezing injury and cellular exhaustion, ideally between 8°C and 10°C where cellular metabolism is preserved producing anti-oxidative metabolites, while maintaining efficient oxygen consumption.

Hypothermic Storage Devices for Donor Lung Preservation

myTEMP 65HC Incubator (Benchmark Scientific)

An overview of the different controlled hypothermic storage devices is summarized under Table 1. The myTEMP 65HC Incubator allows storage at an accurate and stable temperature ranging from 0°C to 60°C. A large viewing window is available for visual monitoring (Figure 13A). This device meets the electrical and technical specifications for use in an operating theatre (cf. infra). It is not portable and does not allow CHS during organ transport.

FIGURE 13

LUNGguard™ (Paragonix)

LUNGguard (Paragonix, Boston, MA, United States), the first commercially available portable device was first used in clinics in 2021 (Duke Hospital, Durham, United States) and focuses primarily on preventing ice-contact related injury during lung CHS [40]. It received Food and Drug Administration (FDA) clearance and a Conformitéee Européenne (CE) mark (Figure 13B). LUNGguard is designed for CHS at a temperature ranging from 4°C to 8°C. Sherpa Cooling technology with phase-changing material must be cooled at −20°C for 48 h and provides CHS up to 40 h. A smartphone application connected to a logger and thermometer in the LUNGguard allows remote real-time monitoring of location and storage temperature. Also, CHS devices exist for heart (SherpaPak) and liver (LIVERguard).

Moreover, recently, BAROguard received FDA-clearance and its first clinical utilization has been reported [41]. In addition to the features of LUNGguard, BAROguard automatically controls airway pressure of donor lungs during preservation within the recommended range, which is relevant during air transport to avoid pressure-related injury.

VITALPACK EVO (E3 CORTEX)

The Class IIa Medical Device VITALPACK^® EVO is an organ transport container that complies with the Directive 93/42/EEC, used for packaging, transport and preservation of organs (Figure 13C). VITALPACK provides storage of all organs at 2°C–8°C. The source of cooling consists of four gel packs which are to be frozen at −18°C for at least 24 h and placed at room temperature for 30 min before inserted into the box. VITALPACK ensures a start temperature inside the box of 8°C, decreasing to >2°C with a preservation duration of minimal 40 h (tests provided by company on website) [42]. It is designed and guaranteed for 10 uses. VITALTRACK is an extra service in the form of a device that allows location and temperature monitoring. No data has been reported on lung preservation. VITALPACK is standard use for all organ preservation in France since 2017, and has recently been implemented in Switzerland (personal communication E3 CORTEX).

X°Port Lung Transport Device (Traferox Technologies Inc.)

X°Port Lung Transport Device (Traferox Technologies Inc.) has been developed by the Toronto Lung Transplant Program (Figure 13D). Its design was inspired by the animal and preliminary clinical research. X°Port has not yet received FDA-clearance or a CE-mark. The device was designed for donor lung storage at 10°C and is being utilized in a multicenter randomized trial with Northern American and European centers [43].

Clinical Studies

The Proof-Of-Concept for 10°C CHS in Lung Transplantation With the myTEMP 65HC Incubator

In 2021, the first clinical proof-of-concept study of donor lung CHS was reported by Toronto. In five bilateral LTx cases, extended 10°C CHS in the myTEMP 65HC incubator was performed to avoid overnight transplantation [9]. After procurement, donor lungs were first transported by SIS. In the transplant center, lungs were transferred to the incubator at 10°C. Total ischemic time was extended up to 16h30. No incidence of primary graft dysfunction grade 3 (PGD3) was observed at 72 h and all patients were reported to be alive at post-LTx day 330. This study was the first to show the possibility of safely bridging the night using CHS.

Multicenter Prospective Non-randomized Trial of 10°C CHS With the myTEMP 65HC Incubator

In 2023, the results of a multicenter prospective non-randomized trial on 10°C CHS were published by Toronto, Vienna, Madrid and Florida [16]. CHS at 10°C in 70 LTx cases was compared to 140 propensity matched SIS cases. Donor lungs were transported with SIS to the transplant center and transferred to the incubator set at 10°C if cross-clamp time was expected between 6 PM and 4 AM. Recipient anesthesia was induced after 6 AM. Authors aimed to study if extended preservation with CHS at 10°C is safe, and to compare outcome with LTx after SIS.

Total ischemic time of the second implanted lung was extended to a median of 14h08. There was no significant difference for PGD3 at 72 h (5.7% for CHS vs. 9.3% for SIS), 30-day -and 1-year survival, showing that extending lung preservation time up to 12 h with 10°C CHS is safe.

GUARDIAN-LUNG Registry for Post-market Registration of LUNGguard Utilization

The Global Utilization and Registry Database for Improved preservAtion of doNor LUNGs (GUARDIAN-LUNG) aims to collect real-world data on LTx with CHS in LUNGguard. In a preliminary analysis, 86 LUNGguard and 90 SIS cases were compared [44]. Incidence of PGD3 at 72 h was not significantly different but a trend with 54% reduction after LUNGguard preservation was observed. Kaplan-Meier analysis revealed a significantly improved survival for LUNGguard vs. SIS with a one-year survival rate of 92.7% vs. 82.2%, respectively.

Another preliminary study compared short-term outcome and costs after LTx with LUNGguard vs. SIS [45]. Total ischemic times were similar for both preservation techniques. The incidence of PGD3 at 72 h and rejection rate prior to discharge and survival were similar.

Interestingly, in 2023, results from the GUARDIAN-heart registry including 569 patients (255 SherpaPak vs. 314 ice) in heart transplantation were reported [46]. Data indicated a favorable outcome after CHS of donor hearts in SherpaPak with significantly lower incidence of PGD and a trend towards reduced need for post-transplant mechanical circulatory support and improved 1-year survival.

Multicenter Randomized Controlled Trial With X°port

In 2023, a multicenter prospective clinical randomized controlled trial (RCT) was set up by Toronto comparing 10°C CHS in the X°Port vs. SIS [43]. The aim of this study is to show non-inferiority of extended preservation at 10°C in X°Port. End-points are PGD3 at 72 h, postoperative recovery, acute rejection, performance status and 1-year survival.

Overnight Bridging of Lung Preservation With CHS

Conventionally, there has been an emphasis on restricting CIT to within the acceptable range of 6–8 h using traditional ice storage [13]. Nevertheless, there have been reports of successful LTx cases exceeding the 8 h timeframe, and retrospective studies revealed inconclusive correlation between ischemia time and post-LTx outcomes [47–49]. Furthermore, within the framework of SIS, the transplant team contends with persistent time constraints and a tendency for overnight transplantation. This situation presents logistical challenges, especially in the context of remote and distant procurements.

The effect of performing transplantation outside regular working hours has been studied for different organs, and available data show potential negative impact on outcome [50]. In a retrospective cohort of 563 LTx cases, a higher incidence of PGD3 was observed within 72 h when reperfusion was between 4 AM and 8 AM [51]. In a propensity matched study on LTx, 187 overnight cases were compared with 187 daytime cases. Overnight transplantation was associated with higher rates of postoperative major events, worse 5-year survival and shorter freedom from bronchiolitis obliterans syndrome [14].

Safely extending ischemic times with CHS can overcome the challenges associated with time pressure. Longer transport time allows procurement in hospitals located further away. Limited capacity at the operating theatre or multi-organ transplants can be managed more easily [52]. Shorter intervals between procurement allow consecutive LTx procedures. Hence, CHS introduces more flexibility for transplant teams without compromising outcome, which benefits healthcare personnel. Daytime transplantation improves overall fitness of transplant teams favoring cognitive and psychomotor skills and reducing the likelihood of errors. An anonymous survey of 7,900 correspondents reported an association of burnout and decreased career satisfaction with overnight surgery. A significantly higher proportion of surgeons working >80 h/week or >2 nights on call/week indicated that they would not become a surgeon again [53]. Furthermore, daytime LTx provides more technical expertise and personnel available. Also, providing a scheduled daytime LTx would attract young professionals and retain more surgeons and transplant personnel.

LUNGguard Utilization and Experience at University Hospitals Leuven

CHS with LUNGguard was introduced in our center (Leuven, Belgium) in November 2022. Our current policy states that CHS with LUNGguard is used for cases with donor cross-clamp after 6 PM with recipient anesthesia starting at 7.30 AM, in cases of logistical limitations to accept valid donor offer, and if a complex recipient procedure is anticipated. By the end of February 2024, CHS with LUNGguard was performed in 24 cases. The average donor age was 60 years (12M/12F), 7 DCD cases were performed. In 18 (75%) cases, LUNGguard was used to extend preservation until daytime. The ischemic time of the second implanted lung exceeded 12 h in 18 (75%) and 15 h in 15 (63%) cases. The average preservation temperature was 6.8°C. Median total ischemia time for the second implanted lung was 15 h with a maximum of 22 h. The incidence of PGD3 at 72 h was 0% and median postoperative time on ventilator was 39 h. One patient died 1 week after LTx, suffering from the consequences of intraoperative ECMO-failure [54, 55].

Leaving the Ice Age Behind: The Dawn of a New Era

Research encompassing historical and recent animal experiments, groundbreaking clinical studies and the development of new preservation devices have shown that CHS of donor lungs is here to stay. The ice box has served transplant teams for decades but an irreversible shift towards use of CHS has set off. Reaching donor hospitals located further away and extending preservation to daytime can increase the number of transplants and improve outcome.

Larger patient numbers and longer follow-up are needed to study the safety of extended CHS preservation with associated reduction of PGD and prolongation of survival. Currently, temperatures for CHS are between 6°C and 10°C, but optimal temperature for CHS has not yet been pinpointed. Another interesting subject is to investigate whether CHS in general or prolonged preservation with CHS improves outcome for extended criteria donor lungs (injury, pneumonia). More research on the optimal preservation duration, temperature and unraveling the mechanism of CHS remain topics for further research. Further investigation is also required to determine whether the advantages of CHS are solely dependent on the presence of oxygen in the alveoli, making them specific to the lung, or if they also apply to other solid organs.

Conclusion

Based on preclinical and clinical data, we reviewed the underlying mechanisms of improved lung preservation with CHS. It was shown that preservation of lungs by CHS better maintains mitochondrial health and cellular viability. The current clinical data supports the feasibility of implementing CHS to safely extend preservation time, and to avoid overnight transplantation. Additional experimental, clinical studies and RCTs are necessary to further define the future of preservation in LTx. Furthermore, the potential benefits of CHS for other solid organs also require thorough investigation.

References

• 1.

  Van RaemdonckDVan SlambrouckJCeulemansLJ. Donor Lung Preservation for Transplantation—Where Do We Go From Here?J Thorac Dis (2022) 14(9):3125–30. 10.21037/jtd-22-949

  • CrossRef
  • Google Scholar

• 2.

  VenutaFVan RaemdonckD. History of Lung Transplantation. J Thorac Dis (2017) 9(12):5458–71. 10.21037/jtd.2017.11.84

  • CrossRef
  • Google Scholar

• 3.

  HaverichAScottWCJamiesonSW. Twenty Years of Lung Preservation--A Review. J Heart Transpl (1985) 4(2):234–40.

  • Google Scholar

• 4.

  HaverichAAzizSScottWCJamiesonSWShumwayNE. Improved Lung Preservation Using Euro-Collins Solution for Flush-Perfusion. Thorac Cardiovasc Surg (1986) 34(6):368–76. 10.1055/s-2007-1022176

  • CrossRef
  • Google Scholar

• 5.

  BaldwinJCFristWHStarkeyTDHarjulaAStarnesVAStinsonEBet alDistant Graft Procurement for Combined Heart and Lung Transplantation Using Pulmonary Artery Flush and Simple Topical Hypothermia for Graft Preservation. Ann Thorac Surg (1987) 43(6):670–3. 10.1016/S0003-4975(10)60249-4

  • CrossRef
  • Google Scholar

• 6.

  CopelandHHayangaJWANeyrinckAMacDonaldPDellgrenGBertolottiAet alDonor Heart and Lung Procurement: A Consensus Statement. J Heart Lung Transplant (2020) 39(6):501–17. 10.1016/j.healun.2020.03.020

  • CrossRef
  • Google Scholar

• 7.

  WilletKDetryOLambermontBMeurisseMDefraigneJOSluse-GoffartCet alEffects of Cold and Warm Ischemia on the Mitochondrial Oxidative Phosphorylation of Swine Lung. Transplantation (2000) 69(4):582–8. 10.1097/00007890-200002270-00020

  • CrossRef
  • Google Scholar

• 8.

  DateHMatsumuraAManchesterJKCooperJMLowryOHCooperJD. Changes in Alveolar Oxygen and Carbon Dioxide Concentration and Oxygen Consumption During Lung Preservation: The Maintenance of Aerobic Metabolism During Lung Preservation. J Thorac Cardiovasc Surg (1993) 105(3):492–501. 10.1016/s0022-5223(19)34232-1

  • CrossRef
  • Google Scholar

• 9.

  AliAWangARibeiroRVPBeroncalELKeshavjeeSAbdelnour-BerchtoldEAet alStatic Lung Storage at 10°C Maintains Mitochondrial Health and Preserves Donor Organ Function. Sci Transl Med (2021) 13:eabf7601. 10.1126/scitranslmed.abf7601

  • CrossRef
  • Google Scholar

• 10.

  Abdelnour-BerchtoldEAliABaciuCBeroncalELWangAHoughOet alEvaluation of 10°C as the Optimal Storage Temperature for Aspiration-Injured Donor Lungs in a Large Animal Transplant Model. J Heart Lung Transplant (2022) 41(12):1679–88. 10.1016/j.healun.2022.08.025

  • CrossRef
  • Google Scholar

• 11.

  SunWWangZCaoJCuiHMaZ. Cold Stress Increases Reactive Oxygen Species Formation via TRPA1 Activation in A549 Cells. Cell Stress Chaperones (2016) 21(2):367–72. 10.1007/s12192-015-0663-3

  • CrossRef
  • Google Scholar

• 12.

  LiuWCChenSBLiuSLingXXuQRYuBTet alInhibition of Mitochondrial Autophagy Protects Donor Lungs for Lung Transplantation Against Ischaemia-Reperfusion Injury in Rats Via the mTOR Pathway. J Cel Mol Med (2019) 23(5):3190–201. 10.1111/jcmm.14177

  • CrossRef
  • Google Scholar

• 13.

  LundLHKhushKKCherikhWSGoldfarbSKucheryavayaAYLevveyBJet alThe Registry of the International Society for Heart and Lung Transplantation: Thirty-Fourth Adult Heart Transplantation Report—2017; Focus Theme: Allograft Ischemic Time. J Heart Lung Transplant (2017) 36(10):1037–46. 10.1016/j.healun.2017.07.019

  • CrossRef
  • Google Scholar

• 14.

  YangZTakahashiTGerullWDHamiltonCSubramanianMPLiuJet alImpact of Nighttime Lung Transplantation on Outcomes and Costs. Ann Thorac Surg (2021) 112:206–13. Elsevier Inc. 10.1016/j.athoracsur.2020.07.060

  • CrossRef
  • Google Scholar

• 15.

  GuoQHLiuQLHuXJLiYZhengJXueWJ. Comparison of Nighttime and Daytime Operation on Outcomes of Kidney Transplant With Deceased Donors: A Retrospective Analysis. Chin Med J (Engl) (2019) 132(4):395–404. 10.1097/CM9.0000000000000056

  • CrossRef
  • Google Scholar

• 16.

  AliAHoetzeneckerKLuis Campo-Cañaveral de la CruzJSchwarzSBarturenMGTomlinsonGet alExtension of Cold Static Donor Lung Preservation at 10°C. NEJM Evid (2023) 2(6):EVIDoa2300008. 10.1056/evidoa2300008

  • CrossRef
  • Google Scholar

• 17.

  WangLSYoshikawaKMiyoshiSNakamotoKHsiehCMYamazakiFet alThe Effect of Ischemic Time and Temperature on Lung Preservation in a Simple Ex Vivo Rabbit Model Used for Functional Assessment. J Thorac Cardiovasc Surg (1989) 98(3):333–42. 10.1016/s0022-5223(19)34378-8

  • CrossRef
  • Google Scholar

• 18.

  DateHLimaOMatsumuraATsujiHd’AvignonDACooperJD. In a Canine Model, Lung Preservation at 10° C Is Superior to That at 4° C: A Comparison of Two Preservation Temperatures on Lung Function and on Adenosine Triphosphate Level Measured by Phosphorus 31-Nuclear Magnetic Resonance. J Thorac Cardiovasc Surg (1992) 103(4):773–80. 10.1016/s0022-5223(19)34961-x

  • CrossRef
  • Google Scholar

• 19.

  NakamotoKMaedaMTaniguchiKTsubotaNKawashimaY. A Study on Optimal Temperature for Isolated Lung Preservation. Ann Thorac Surg (1992) 53(1):101–8. 10.1016/0003-4975(92)90766-W

  • CrossRef
  • Google Scholar

• 20.

  KeshavjeeSHYamazakiFCardosoPFMcRitchieDIPattersonGACooperJD. A Method for Safe Twelve-Hour Pulmonary Preservation. J Thorac Cardiovasc Surg (1989) 98(4):529–34. 10.1016/s0022-5223(19)34354-5

  • CrossRef
  • Google Scholar

• 21.

  MayerEPuskasJDCardosoPFGShiSSlutskyASPattersonGA. Reliable Eighteen-Hour Lung Preservation at 4 Degrees and 10 Degrees C by Pulmonary Artery Flush After High-Dose Prostaglandin E1 Administration. J Thorac Cardiovasc Surg (1992) 103(6):1136–42. 10.1016/s0022-5223(19)34878-0

  • CrossRef
  • Google Scholar

• 22.

  SteenSSjöbergTMassaGEricssonLLindbergL. Safe Pulmonary Preservation for 12 Hours With Low-Potassium-Dextran Solution. Ann Thorac Surg (1993) 55(2):434–40. 10.1016/0003-4975(93)91016-G

  • CrossRef
  • Google Scholar

• 23.

  SteenSKimbladPOSjöbergTLindbergLIngemanssonRMassaG. Safe Lung Preservation for Twenty-Four Hours With Perfadex. Ann Thorac Surg (1994) 57(2):450–7. 10.1016/0003-4975(94)91016-2

  • CrossRef
  • Google Scholar

• 24.

  LideD. R. (2004) CRC Handbook of Chemistry and Physics (85th ed.), Section 6: [Fluid Properties]. p983-1003 Boca Raton, FL: CRC Press. ISBN 978-0-8493-0485-9.

  • Google Scholar

• 25.

  RobicsekFDuncanGDRiceHERobicsekSA. Experiments With a Bowl of Saline: The Hidden Risk of Hypothermic-Osmotic Damage During Topical Cardiac Cooling. J Thorac Cardiovasc Surg (1989) 97(3):461–6. 10.1016/s0022-5223(19)34587-8

  • CrossRef
  • Google Scholar

• 26.

  PatelPBulkaBChurchillLTajimaMAndersonL. (253) Ice Is Not 4c: Thermodynamic Characterization of Lungs and Hearts Preserved on Ice. J Heart Lung Transplant (2023) 42(4):S122–3. 10.1016/j.healun.2023.02.1557

  • CrossRef
  • Google Scholar

• 27.

  CenikIVan SlambrouckJPrisciandaroEProvoostA-LVan RaemdonckDECeulemansLJ. Measuring Donor Lung Temperature in Clinical Lung Transplantation: Controlled Hypothermic Storage Versus Static Ice Storage. J Heart Lung Transplant (2024). Published online.

  • Google Scholar

• 28.

  DiasCLAla-NissilaTWong-ekkabutJVattulainenIGrantMKarttunenM. The Hydrophobic Effect and Its Role in Cold Denaturation. Cryobiology (2010) 60(1):91–9. 10.1016/j.cryobiol.2009.07.005

  • CrossRef
  • Google Scholar

• 29.

  ChenJLiuXHuYChenXTanS. Cryopreservation of Tissues and Organs: Present, Bottlenecks, and Future. Front Vet Sci (2023) 10:1201794. 10.3389/fvets.2023.1201794

  • CrossRef
  • Google Scholar

• 30.

  WestAPShadelGS. Mitochondrial DNA in Innate Immune Responses and Inflammatory Pathology. Nat Rev Immunol (2017) 17(6):363–75. 10.1038/nri.2017.21

  • CrossRef
  • Google Scholar

• 31.

  GuoCSunLChenXZhangD. Oxidative Stress, Mitochondrial Damage and Neurodegenerative Diseases. Neural Regen Res (2013) 8(21):2003–14. 10.3969/j.issn.1673-5374.2013.21.009

  • CrossRef
  • Google Scholar

• 32.

  FerrariRSAndradeCF. Oxidative Stress and Lung Ischemia-Reperfusion Injury. Oxid Med Cel Longev (2015) 2015:590987. 10.1155/2015/590987

  • CrossRef
  • Google Scholar

• 33.

  ZimmermanBJGrangerDN. Mechanisms of Reperfusion Injury. Am J Med Sci (1994) 307(4):284–92. 10.1097/00000441-199404000-00009

  • CrossRef
  • Google Scholar

• 34.

  AllenMMillettPDawesERushtonN. Lactate Dehydrogenase Activity as a Rapid and Sensitive Test for the Quantification of Cell Numbers In Vitro. Clin Mater (1994) 16(4):189–94. 10.1016/0267-6605(94)90116-3

  • CrossRef
  • Google Scholar

• 35.

  PrasadAAndrewsNPPadderFAHusainMQuyyumiAA. Glutathione Reverses Endothelial Dysfunction and Improves Nitric Oxide Bioavailability. J Am Coll Cardiol (1999) 34(2):507–14. 10.1016/S0735-1097(99)00216-8

  • CrossRef
  • Google Scholar

• 36.

  HasanuzzamanMBorhannuddin BhuyanMHMAneeTIParvinKNaharKMahmudJAet alRegulation of Ascorbate-Glutathione Pathway in Mitigating Oxidative Damage in Plants Under Abiotic Stress. Antioxidants (2019) 8(9):384. 10.3390/antiox8090384

  • CrossRef
  • Google Scholar

• 37.

  MartinJLCostaASHGruszczykAVBeachTEAllenFMPragHAet alSuccinate Accumulation Drives Ischaemia-Reperfusion Injury During Organ Transplantation. Nat Metab (2019) 1:966–74. 10.1038/s42255-019-0115-y

  • CrossRef
  • Google Scholar

• 38.

  CordesTLucasADivakaruniASMurphyANCabralesPMetalloCM. Itaconate Modulates Tricarboxylic Acid and Redox Metabolism to Mitigate Reperfusion Injury. Mol Metab (2020) 32:122–35. 10.1016/j.molmet.2019.11.019

  • CrossRef
  • Google Scholar

• 39.

  ChouchaniETPellVRGaudeEAksentijevićDSundierSYRobbELet alIschaemic Accumulation of Succinate Controls Reperfusion Injury Through Mitochondrial ROS. Nature (2014) 515(7527):431–5. 10.1038/nature13909

  • CrossRef
  • Google Scholar

• 40.

  Paragonixtechnologies. Paragonix Announces First-In-Man Use of LUNGguard^TM Donor Lung Preservation System by Duke Hospital (2021). Available from: https://www.paragonixtechnologies.com/news/paragonix-announces-first-in-man-use-of-lungguard-tm-donor-lung-preservation-system-by-duke-hospital (Accessed February 27, 2024).

  • Google Scholar

• 41.

  AdamL. Paragonix Announces World’s First-In-Human Use of BAROguard^TM Donor Lung Preservation System by Leading Academic Medical Center. WALTHAM, Mass: Businesswire (2023). Available from: https://www.businesswire.com/news/home/20231117736795/en/Paragonix-Announces-World%E2%80%99s-First-In-Human-Use-of-BAROguard%E2%84%A2-Donor-Lung-Preservation-System-by-Leading-Academic-Medical-Center?utm_campaign=shareaholic&utm_medium=linkedin&utm_source=socialnetwork (Accessed November 24, 2023).

  • Google Scholar

• 42.

  E3 Cortex. Vitalpack Evo. Mortefontaine, France: E3 Cortex (2021). Available from: https://e3cortex.com/en/transplant/42-vitalpack-evo.html (Accessed November 24, 2023).

  • Google Scholar

• 43.

  NCT. 10°C vs 4°C Lung Preservation RCT (2023). Available from: https://clinicaltrials.gov/study/NCT05898776 (Accessed November 24, 2023).

  • Google Scholar

• 44.

  HaneyJHartwigMLangerNSanchezPBushE. (68) Not Too Warm, Not Too Cold: Real-World Multi-Center Outcomes with Elevated Hypothermic Preservation of Donor Lungs. J Heart Lung Transplant (2023) 42(4):S39–S40. 10.1016/j.healun.2023.02.084

  • CrossRef
  • Google Scholar

• 45.

  PontulaAHalpernSEBottigerBAHaneyJCKlapperJA. Comparing the Paragonix LUNGguard Donor Lung Preservation System to Traditional Ice Storage the Inclusion of Biomarker Scoring During Ex-Vivo Lung Perfusion Can Improve Organ Utilization and Patient Outcomes-A Retrospective. Single Cent Study AbstrS257.

  • Google Scholar

• 46.

  ShudoYLeaccheMCopelandHSilvestrySPhamSMMolinaEet alA Paradigm Shift in Heart Preservation: Improved Post-Transplant Outcomes in Recipients of Donor Hearts Preserved With the SherpaPak System. ASAIO J (2023) 69:993–1000. 10.1097/MAT.0000000000002036

  • CrossRef
  • Google Scholar

• 47.

  HalpernSEAuSKesseliSJKrischakMKOlasoDGBottigerBAet alLung Transplantation Using Allografts With More Than 8 Hours of Ischemic Time: A Single-Institution Experience. J Heart Lung Transplant (2021) 40(11):1463–71. 10.1016/j.healun.2021.05.008

  • CrossRef
  • Google Scholar

• 48.

  GammieJSStukusDRPhamSMHattlerBGMcGrathMFMcCurryKRet alEffect of Ischemic Time on Survival in Clinical Lung Transplantation. Ann Thorac Surg (1999) 68(6):2015–9. discussion 2019-20. 10.1016/s0003-4975(99)00903-0

  • CrossRef
  • Google Scholar

• 49.

  GrimmJCValeroVKilicAMagruderJTMerloCAShahPDet alAssociation Between Prolonged Graft Ischemia and Primary Graft Failure or Survival Following Lung Transplantation. JAMA Surg (2015) 150(6):547–53. 10.1001/jamasurg.2015.12

  • CrossRef
  • Google Scholar

• 50.

  HendrikxJVan RaemdonckDPirenneJFieuwsSRexS. Outcome of Transplantation Performed Outside the Regular Working Hours: A Systematic Review and Meta-Analysis of the Literature. Transpl Rev (2018) 32(3):168–77. 10.1016/j.trre.2018.05.001

  • CrossRef
  • Google Scholar

• 51.

  CunninghamPSMaidstoneRDurringtonHJVenkateswaranRVCypelMKeshavjeeSet alIncidence of Primary Graft Dysfunction After Lung Transplantation Is Altered by Timing of Allograft Implantation. Thorax (2019) 74(4):413–6. 10.1136/thoraxjnl-2018-212021

  • CrossRef
  • Google Scholar

• 52.

  CeulemansLJMonbaliuDVerslypeCvan der MerweSLalemanWVosRet alCombined Liver and Lung Transplantation With Extended Normothermic Lung Preservation in a Patient With End-Stage Emphysema Complicated by Drug-Induced Acute Liver Failure. Am J Transplant (2014) 14(10):2412–6. 10.1111/ajt.12856

  • CrossRef
  • Google Scholar

• 53.

  BalchCMShanafeltTDDyrbyeLSloanJARussellTRBechampsGJet alSurgeon Distress as Calibrated by Hours Worked and Nights on Call. J Am Coll Surg (2010) 211(5):609–19. 10.1016/j.jamcollsurg.2010.06.393

  • CrossRef
  • Google Scholar

• 54.

  NovysedlakRProvoostALLangerNBVan SlambrouckJBarbarossaACenikIet alExtended Ischemic Time (>15 Hours) Using Controlled Hypothermic Storage in Lung Transplantation: A Multicenter Experience. J Heart Lung Transplant (2024). Published online February 2024. 10.1016/j.healun.2024.02.006

  • CrossRef
  • Google Scholar

• 55.

  ProvoostA-LVan SlambrouckJPrisciandaroENovysedlakRBarbarossaACeulemansLJ. Controlled Hypothermic Static Lung Storage With Portable Preservation Device: A Single-Centre 1 Year Experience. Brussels, Belgium: Belgian Transplantation Society.

  • Google Scholar